Key clinical point: Lenalidomide, BTK inhibitors, Bcl-2 inhibitors, and immune therapy, among others, present promising results in vitro.
Major finding: Potential mechanisms fall into two pathways: the CD5-mediated BCR-dependent pathway and the CD5-mediated BCR-independent pathway.
Study details: Review of the biology, mechanisms, and treatment approaches in de novo CD5+ DLBCL.
Disclosures: The study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Jiangxi province. The authors reported having no disclosures.
Xu Y et al. Clinical Lymphoma Myeloma and Leukemia. 2020; doi.org/10.1016/j.clml.2020.05.003.